BF7 Monoclonal Antibody Markers for Early Colorectal Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer detection methods are invasive, costly, and lack sensitivity and specificity for early detection, particularly for colorectal cancer, and there is a need for non-invasive, affordable, and accurate biomarkers for early cancer detection and relapse monitoring.
Innovation Solution
A non-human, non-naturally occurring monoclonal antibody, BF7, is used to detect a collection of polypeptides specific to colorectal cancer, allowing for sensitive and specific detection in bodily fluids, enabling early detection and monitoring of disease relapse through quantitative measurement of protein markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive procedures such as biopsy are used for cancer detection, then detection accuracy can be improved, but patient comfort and ease of testing deteriorate
Solution Approach 1:
The patent uses circulating tumor DNA (ctDNA) as an intermediary biomarker that bridges the gap between invasive tissue biopsy and non-invasive blood testing. The ctDNA serves as a mediator that carries cancer-specific genetic information from the tumor into the bloodstream, enabling detection without direct tissue sampling while maintaining high diagnostic accuracy through molecular analysis of circulating nucleic acids.
Solution Approach 2:
The patent replaces the mechanical invasive procedure of tissue biopsy with a molecular detection method analyzing circulating DNA in blood. Instead of mechanically extracting tissue samples through needles or surgical instruments, the system uses molecular biology techniques to detect cancer markers in liquid blood samples, substituting mechanical invasion with biochemical analysis to achieve similar or superior detection capability.
2Ease of operation
If existing cancer markers such as CEA, CA-15, CA-19, and CA-125 are used, then detection can be performed in body fluids, but sensitivity and specificity for early-stage cancer deteriorate
Solution Approach 1:
The patent changes the detection parameter from traditional protein-based tumor markers (CEA, CA-15, CA-19, CA-125) to DNA-based molecular markers analyzing circulating tumor DNA. This parameter change enables detection at earlier stages by identifying genetic alterations and mutations in ctDNA that precede the secretion of traditional protein markers, thereby improving sensitivity while maintaining non-invasive blood testing.
Solution Approach 2:
The patent uses circulating tumor DNA as a molecular copy of the original tumor's genetic profile. Instead of requiring direct analysis of tumor tissue or detection of secreted proteins, the system analyzes copies of tumor DNA that have been released into the bloodstream, providing a portable and stable molecular fingerprint that preserves cancer-specific genetic information for high-accuracy detection.
3Measurement precision
If multiple existing markers are combined for better detection, then diagnostic accuracy improves, but test complexity and cost increase
Solution Approach 1:
The patent merges multiple detection capabilities into a single integrated ctDNA analysis platform. By combining genetic mutation detection, methylation analysis, and molecular profiling into one comprehensive test, the system achieves high diagnostic accuracy equivalent to multiple separate marker tests while reducing overall complexity through unified sample processing and integrated data analysis.
Solution Approach 2:
The patent develops a universal ctDNA detection platform that can identify multiple types of cancer markers and genetic alterations through a single test methodology. This multi-functional approach allows the same test to detect various cancer types and stages by analyzing different molecular features of circulating DNA, eliminating the need for multiple separate specialized tests and reducing overall system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
BF7 antibody provides high sensitivity and specificity for detecting early-stage colorectal cancer and relapse, facilitating timely intervention and reducing healthcare costs by enabling non-invasive, cost-effective screening and surveillance.
Implementation Method 1
A non-human, non-naturally occurring monoclonal antibody, BF7, is used to detect a collection of polypeptides specific to colorectal cancer
Data Source
AI summary
Biomarkers can be assessed for a variety of uses, including screening, detection, diagnosis, prognosis, risk prediction, disease progression, recurrence, selection of treatment, therapy response, to evaluate a subject's health status, whether the subject presents with no evidence of disease, or a benign or malignant condition such as cancer. Compositions (antibodies, polypeptide and polynucleotide markers) and methods are provided herein, which find application in the early detection of cancer, in the early detection of disease relapse and in monitoring therapy response.